EMEA-001407-PIP02-15-M01

  • Email
  • Help

Overview

Product details for Opdivo
Invented nameOpdivo
Active substance

Nivolumab

Decision numberP/0004/2017
PIP numberEMEA-001407-PIP02-15-M01
Pharmaceutical form(s)Concentrate for solution for infusion
Condition(s)/indication(s)

Treatment of malignant neoplasms of the central nervous system

Treatment of malignant neoplasms of lymphoid tissue

Route(s) of administrationIntravenous use
PIP applicant

Bristol-Myers Squibb Pharma EEIG
United Kingdom
Tel. +44 1895523740
Fax +44 1895523677
E-mail: medical.information@bms.com

Decision typePM: decision on the application for modification of an agreed PIP

Decision